financetom
Business
financetom
/
Business
/
Commerzbank on The Canadian Dollar After Central Bank 25bps Rate Cut Wednesday
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Commerzbank on The Canadian Dollar After Central Bank 25bps Rate Cut Wednesday
Jul 25, 2024 4:56 AM

07:20 AM EDT, 07/25/2024 (MT Newswires) -- Bank of Canada (BoC) cut interest rates again on Wednesday by 25 basis points to 4.50%, as expected, said Commerbank.

At the same time, BoC made clear that further rate cuts are likely to follow, wrote the bank in a note to clients. BoC Governor Tiff Macklem stated that decisions would be made "one at a time", meaning that there is no predetermined path of rate cuts.

However, the governor also stressed that it was reasonable to expect further rate cuts, stated Commerzbank. With the year-on-year inflation rate likely to reach a value close to the target in the next two months due to base effects, there is little to argue against further rate cuts.

Unless inflation unexpectedly picks up "significantly," another rate cut in early September is likely to remain the baseline scenario, pointed out the bank.

The general impression was that the BoC was shifting its focus from inflation to growth concerns, added Commerzbank. Accordingly, the growth forecasts for 2024 and 2025 were lowered again.

As a result, there is much to suggest that the Canadian dollar (CAD or loonie) will remain under pressure in the coming months: after all, the BoC is likely to cut rates further and the real economy will benefit from the rate cuts only with a time lag. As a consequence, the bank maintains its forecast of a weaker CAD through to the end of the year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Olaplex Holdings Insider Sold Shares Worth $803,366, According to a Recent SEC Filing
Olaplex Holdings Insider Sold Shares Worth $803,366, According to a Recent SEC Filing
Dec 13, 2024
04:12 PM EST, 12/13/2024 (MT Newswires) -- Amanda Baldwin, Director, Chief Executive Officer, on December 11, 2024, sold 382,555 shares in Olaplex Holdings ( OLPX ) for $803,366. Following the Form 4 filing with the SEC, Baldwin has control over a total of 2,822,500 shares of the company, with 2,822,500 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1868726/000186872624000100/xslF345X05/wk-form4_1734123752.xml ...
Market Chatter: Microsoft, Google, Other Firms to Be Given 'Gatekeeper' Status to Control AI Chip Access
Market Chatter: Microsoft, Google, Other Firms to Be Given 'Gatekeeper' Status to Control AI Chip Access
Dec 13, 2024
04:11 PM EST, 12/13/2024 (MT Newswires) -- Microsoft ( MSFT ) and Google ( GOOG ) and other major tech companies will be granted the role of global gatekeepers by the US to control access to high-value artificial intelligence chips, Reuters reported Friday, citing sources with knowledge of the matter. The companies will reportedly be required to follow strict US...
Northwestern Energy Group Insider Sold Shares Worth $384,430, According to a Recent SEC Filing
Northwestern Energy Group Insider Sold Shares Worth $384,430, According to a Recent SEC Filing
Dec 13, 2024
04:07 PM EST, 12/13/2024 (MT Newswires) -- Anthony Thomas Clark, Director, on December 12, 2024, sold 7,400 shares in Northwestern Energy Group ( NWE ) for $384,430. Following the Form 4 filing with the SEC, Clark has control over a total of 16,816 shares of the company, with 16,816 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1993004/000199300424000118/xslF345X05/wk-form4_1734123847.xml ...
US FDA lifts partial clinical hold on BioNTech cancer drug study
US FDA lifts partial clinical hold on BioNTech cancer drug study
Dec 13, 2024
Dec 13 (Reuters) - BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted the partial clinical hold on its late-stage trial studying its drug for a type of lung cancer. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved